5 results about "Hydrolase inhibitor" patented technology

The application belongs to the field of new use of drugs, and more particularly relates to application of 3-Deazaadenosine in preparation of a therapeutic drug for treating hypertrophic scars. 3-Deazaadenosine is an S-adenosylhomocysteine hydrolase inhibitor, and has antiviral, anti-inflammatory and other activities. Experiments show that the compound can significantly reduce the modification level of m6A in fibroblasts in hypertrophic scar tissue, inhibit the proliferation and migration of fibroblasts, promote the apoptosis of fibroblasts, and also can reduce the expression levels of Collagen I, Collagen III and alpha-SMA in fibroblasts. Therefore, the compound can be used for preparing a drug for relieving or treating hypertrophic scars, and has important clinical application value.

Disclosed are a long-acting oral pharmaceutical comprising a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) and use thereof. Specifically, disclosed is a long-acting oral pharmaceutical formulation comprising a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, adjuvants, or excipients. The long-acting oral pharmaceutical formulation is suitable for administration at intervals of once every one week or longer, making it suitable for long-term administration in the treatment of chronic anemia.

The present invention provides novel heterocyclic compounds having the general formula (I) wherein X, Y, A, B, C and R 1 as described herein; compositions comprising the compounds; methods of making the compounds; and methods of using the compounds as soluble epoxide hydrolase inhibitors.(I)

The disclosure provides compounds, in part, compounds of Formula I or Formula II and their use in treating medical diseases or disorders, such as neurodegenerative diseases, e.g., Parkinson's disease. Pharmaceutical compositions and methods of making compounds of the disclosure are provided. The compounds are contemplated to be modulators, e.g., inhibitors, of cyclic ADP ribose hydrolase (CD38).